EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An open-label interventional study on efficacy and safety of 25 µg of daily calcifediol capsule versus 100 µg of cholecalciferol sachets in apparently healthy volunteers

Ravi Shah iD, Liza Das iD, Dipika Bansal, Naresh Sachdeva, Michael F Holick, Pinaki Dutta iD, Sanja Medenica, Raman Kumar Marwaha iD

Journal of Nutritional Science · 2026

DOI: 10.1017/jns.2025.10064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nutritional Science, 2026. Verfasst von Ravi Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Cholecalciferol, Vitamin D Deficiency, Calcifediol, Dietary Supplements. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the multiple advantages of 25-hydroxyvitamin D (calcifediol or 25(OH)D) compared to cholecalciferol, it is used sparingly. This study was planned to assess the safety and efficacy of supplementing daily 25 µg of calcifediol capsules vis-a-vis 100 µg (4000 IU) of cholecalciferol sachets in apparently healthy individuals with vitamin D deficiency in Chandigarh, India (latitude 30.7° North, 76.8° East). It was a prospective, interventional study to evaluate the effects of calcifediol vis-a-vis cholecalciferol. Following initial screening of 70 subjects in each group, 62 were included in the calcifediol and 41 in the cholecalciferol group. Forty-six from calcifediol and 37 from cholecalciferol group completed the 6-month follow up. There was a significant increase in serum 25(OH)D (355% in cholecalciferol & 574% in calcifediol groups, respectively, p < 0.001) and 1,25 (OH) 2 D ( p < 0.001) with a marked decrease in iPTH ( p < 0.001) and ALP ( p = 0.016) in both groups. Though serum ALP decreased significantly more in the calcifediol group than the cholecalciferol group, no appreciable difference in other biochemical parameters was noted between the groups. No episodes of hypercalcaemia or incidence of new renal stone disease were observed during follow-up. However, hypercalciuria (spot urine calcium creatinine > 0.2 mg/mg) was noted in 8/46 individuals in the calcifediol group and 5/37 individuals in the cholecalciferol group at final visit with no significant difference between two groups. This study establishes the efficacy and safety of correcting vitamin D deficiency with daily 25 µg calcifediol capsules as an alternative to 4000 IU (100 µg) cholecalciferol sachets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholecalciferolVitamin D DeficiencyCalcifediolDietary SupplementsHumansMaleFemaleAdultProspective StudiesCapsulesMiddle AgedVitamin DParathyroid HormoneIndiaYoung AdultCalcium

Stichwörter der Autor:innen

25(OH) D, 25 hydroxy vit. D25(OH)D3CalcifediolCholecalciferolECLIA, Electrochemiluminescence ImmunoassayVitamin D deficiencyiPTH, intact parathyroid hormoneβCTX Beta-Cross Laps, (C-terminal telopeptide of type 1 collagen)

Substanzen

CholecalciferolCalcifediolCapsules25-hydroxyvitamin DVitamin DParathyroid HormoneCalcium

Autor:innen und Institutionen

  • Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Telemedicine, PGIMER, Chandigarh, India.
  • Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India.
  • Department of Medicine, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University School of Medicine, Boston, MA, USA.
  • Department of Endocrinology, Internal Medicine Clinic, Clinical center of Montenegro, University of Montenegro, Podgorica, Montenegro.
  • Consultant Endocrinologist and Scientific Advisor, International Life Sciences Institute (ILSI, India) and President Society for Endocrine Health Care of Elderly, Adolescents and Children (SEHEAC), New Delhi, India.

ORCID-Profile: Ravi Shah, Liza Das, Pinaki Dutta, Raman Kumar Marwaha

Zitieren

APA

Shah, R., Das, L., Bansal, D., Sachdeva, N., Holick, M. F., Dutta, P., Medenica, S., & Marwaha, R. K. (2026). An open-label interventional study on efficacy and safety of 25 µg of daily calcifediol capsule versus 100 µg of cholecalciferol sachets in apparently healthy volunteers. Journal of Nutritional Science. https://doi.org/10.1017/jns.2025.10064

Vancouver

Shah R, Das L, Bansal D, Sachdeva N, Holick MF, Dutta P, et al. An open-label interventional study on efficacy and safety of 25 µg of daily calcifediol capsule versus 100 µg of cholecalciferol sachets in apparently healthy volunteers. Journal of Nutritional Science. 2026. doi:10.1017/jns.2025.10064

BibTeX
@article{Shah2026,
  author = {Shah, Ravi and Das, Liza and Bansal, Dipika and Sachdeva, Naresh and Holick, Michael F and Dutta, Pinaki and Medenica, Sanja and Marwaha, Raman Kumar},
  title = {An open-label interventional study on efficacy and safety of 25 µg of daily calcifediol capsule versus 100 µg of cholecalciferol sachets in apparently healthy volunteers},
  journal = {Journal of Nutritional Science},
  year = {2026},
  doi = {10.1017/jns.2025.10064}
}
Kostenlos starten →